<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://wiki.tiffa.net/w/index.php?action=history&amp;feed=atom&amp;title=Translations%3AAntihypertensive_drug%2F9%2Fen</id>
	<title>Translations:Antihypertensive drug/9/en - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://wiki.tiffa.net/w/index.php?action=history&amp;feed=atom&amp;title=Translations%3AAntihypertensive_drug%2F9%2Fen"/>
	<link rel="alternate" type="text/html" href="https://wiki.tiffa.net/w/index.php?title=Translations:Antihypertensive_drug/9/en&amp;action=history"/>
	<updated>2026-09-30T17:19:30Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.43.0</generator>
	<entry>
		<id>https://wiki.tiffa.net/w/index.php?title=Translations:Antihypertensive_drug/9/en&amp;diff=72919&amp;oldid=prev</id>
		<title>FuzzyBot: Importing a new version from external source</title>
		<link rel="alternate" type="text/html" href="https://wiki.tiffa.net/w/index.php?title=Translations:Antihypertensive_drug/9/en&amp;diff=72919&amp;oldid=prev"/>
		<updated>2023-10-20T03:55:52Z</updated>

		<summary type="html">&lt;p&gt;Importing a new version from external source&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;==ACE inhibitors==&lt;br /&gt;
[[File:Captopril skeletal.svg|thumb|[[Captopril]], the prototypical ACE inhibitor]]&lt;br /&gt;
[[ACE inhibitor]]s inhibit the activity of [[angiotensin-converting enzyme]] (ACE), an enzyme responsible for the conversion of angiotensin I into [[angiotensin]] II, a potent [[vasoconstrictor]].&lt;br /&gt;
* [[captopril]]&lt;br /&gt;
* [[enalapril]]&lt;br /&gt;
* [[fosinopril]]&lt;br /&gt;
* [[lisinopril]]&lt;br /&gt;
* [[moexipril]]&lt;br /&gt;
* [[perindopril]]&lt;br /&gt;
* [[quinapril]]&lt;br /&gt;
* [[ramipril]]&lt;br /&gt;
* [[trandolapril]]&lt;br /&gt;
* [[benazepril]]&lt;br /&gt;
A systematic review of 63 trials with over 35,000 participants indicated ACE inhibitors significantly reduced doubling of serum creatinine levels compared to other drugs (ARBs, α blockers, β blockers, etc.), and the authors suggested this as a first line of defense. The AASK trial showed that ACE inhibitors are more effective at slowing down the decline of [[kidney function]] compared to [[calcium channel blockers]] and [[beta blockers]]. As such, ACE inhibitors should be the drug treatment of choice for patients with [[chronic kidney disease]] regardless of race or diabetic status.&lt;/div&gt;</summary>
		<author><name>FuzzyBot</name></author>
	</entry>
</feed>